OTCMKTS:UCBJF UCB (UCBJF) Stock Price, News & Analysis $270.35 -11.90 (-4.22%) As of 05/22/2026 12:05 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesSEC FilingsShort InterestBuy This Stock About UCB Stock (OTCMKTS:UCBJF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get UCB alerts:Sign Up Key Stats Today's Range$270.35▼$289.8450-Day Range$270.35▼$334.0952-Week Range$178.54▼$345.39Volume4,139 shsAverage Volume793 shsMarket Capitalization$51.10 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview UCB S.A. is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions. Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline. Notable medicines associated with UCB include Cimzia (certolizumab pegol), used in inflammatory and autoimmune conditions, and antiepileptic agents such as levetiracetam (Keppra) and brivaracetam (Briviact). UCB invests in R&D across discovery, clinical development and lifecycle management and frequently collaborates with academic groups, biotechnology partners and contract research organizations to advance novel mechanisms and delivery approaches. Headquartered in Brussels, UCB operates internationally, serving patients and healthcare systems across Europe, North America, Asia-Pacific and other regions. The company is managed through an executive leadership team and overseen by a board of directors; it also maintains manufacturing, regulatory and commercial functions to support global product supply and market access. UCB’s strategic priorities emphasize scientific innovation, targeted therapeutic development and partnerships aimed at addressing unmet medical needs in neurology and immunology.AI Generated. May Contain Errors. Read More Receive UCBJF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UCBJF Stock News HeadlinesUCB SA (OTCMKTS:UCBJF) Given Average Recommendation of "Buy" by BrokeragesMay 14, 2026 | americanbankingnews.comBelgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billionMay 3, 2026 | reuters.comWhere did Vanguard quietly put $101 billion?Vanguard holds $101 billion in three AI companies most investors have never heard of. BlackRock holds $82 billion. State Street, $47 billion - and that's before counting Geode, Morgan Stanley, JPMorgan, and T. Rowe Price. Analyst George Gilder, who spotted the iPhone a decade early, calls them the 'Trillion Dollar Triangle' - chips he says could do in minutes what today's AI data centers do in hours, using up to 90% less energy. He believes the window to get positioned before the broader market catches on may already be closing. | Eagle Publishing (Ad)Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15BApril 17, 2026 | seekingalpha.comBelgium's UCB in autoimmune drug deal with AntengeneMarch 3, 2026 | reuters.comDay by Day maintains UCB (UCBJF) buy recommendationDecember 17, 2025 | msn.comUCB price target raised to EUR 300 from EUR 230 at JPMorganDecember 8, 2025 | msn.comUCB removed from European Conviction List at Goldman SachsNovember 4, 2025 | msn.comSee More Headlines UCBJF Stock Analysis - Frequently Asked Questions How have UCBJF shares performed this year? UCB's stock was trading at $293.58 at the beginning of the year. Since then, UCBJF stock has decreased by 7.9% and is now trading at $270.35. How do I buy shares of UCB? Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/23/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:UCBJF CIK1290640 Webwww.ucb.com Phone(322) 559-9999Fax32-2559-9900Employees9,083Year Founded1928Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.33 Current Ratio1.19 Quick Ratio0.78 Sales & Book Value Annual Sales$5.27 billion Price / Sales9.70 Cash Flow$11.61 per share Price / Cash Flow23.28 Book Value$50.52 per share Price / Book5.35Miscellaneous Outstanding Shares189,020,000Free FloatN/AMarket Cap$51.10 billion OptionableNot Optionable Beta0.47 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:UCBJF) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYou have until June 1Macroeconomic strategist Dr. Mark Skousen believes June 1 marks a critical turning point for one of the most o...The Oxford Club | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Share UCB With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
